Top

Published in:

01-06-2000 | Review

Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates

Authors: Rania Kairouz, Roger J Daly

Published in: Breast Cancer Research | Issue 3/2000

Abstract

The past decade has seen the definition of key signalling pathways downstream of receptor tyrosine kinases (RTKs) in terms of their components and the protein-protein interactions that facilitate signal transduction. Given the strong evidence that links signalling by certain families of RTKs to the progression of breast cancer, it is not surprising that the expression profile of key downstream signalling intermediates in this disease has also come under scrutiny, particularly because some exhibit transforming potential or amplify mitogenic signalling pathways when they are overexpressed. Reflecting the diverse cellular processes regulated by RTKs, it is now clear that altered expression of such signalling proteins in breast cancer may influence not only cellular proliferation (eg Grb2) but also the invasive properties of the cancer cells (eg EMS1/cortactin).

Pawson T, Scott J: Signaling through scaffold, anchoring and adaptor proteins. Science. 1997, 278: 2075-2080. 10.1126/science.278.5346.2075.CrossRefPubMed

Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron. 1992, 9: 383-391.CrossRefPubMed

Mayer B: Clamping down on Src activity. Curr Biol. 1997, 7: R295-R298. 10.1016/S0960-9822(06)00141-2.CrossRefPubMed

Jacobs C, Rubsamen H: Expression of pp60^c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983, 43: 1696-1702.PubMed

Rosen N, Bolen JB, Schwartz AM, et al: Analysis of pp60^c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem. 1986, 261: 13754-13759.PubMed

Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 1989, 49: 516-521.PubMed

Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, et al: Characterisation of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res. 1992, 52: 4773-4778.PubMed

Verbeek B, Vroom T, Adriaansen-Slot S, et al: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 1996, 180: 383-388. 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.3.CO;2-E.CrossRefPubMed

Daly RJ: Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors. 1999, 16: 255-263.CrossRefPubMed

10.

Pinkas-Kramarski R, Alroy I, Yarden Y: ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signalling. J Mam Gland Biol Neoplasia. 1997, 2: 97-107. 10.1023/A:1026343528967.CrossRef

11.

Egan C, Pang A, Durda D, et al: Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 1999, 18: 1227-1237. 10.1038/sj/onc/1202233. This paper represents the first demonstration that a protein tyrosine phosphatase activity directed towards c-Src Tyr530 is upregulated in breast cancer cells.CrossRefPubMed

12.

Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ: Tyrosine kinase signalling in breast cancer: EGF receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000,

13.

Andrechek ER, Muller WJ: Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2000,

14.

van der Geer P, Hunter T: Receptor protein tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol. 1994, 10: 251-337. 10.1146/annurev.cellbio.10.1.251.CrossRefPubMed

15.

Arteaga CL, Johnson MD, Todderud G, et al: Elevated content of the tyrosine kinase substrate phospholipase C-γl in primary human breast carcinomas. Proc Natl Acad Sci USA. 1991, 88: 10435-10439.CrossRefPubMedPubMedCentral

16.

Chen P, Gupta K, Wells A: Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol. 1994, 124: 547-555.CrossRefPubMed

17.

Daly RJ, Binder MD, Sutherland RL: Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene. 1994, 9: 2723-2727.PubMed

18.

Verbeek B, Adriaansen-Slot S, Rijksen G, Vroom T: Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol. 1997, 183: 195-203. 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.3.CO;2-P.CrossRefPubMed

19.

Suen KL, Bustelo XR, Pawson T, Barbacid M: Molecular cloning of the mouse grb2 gene: differential expression of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol Cell Biol. 1993, 13: 5500-5512.CrossRefPubMedPubMedCentral

20.

Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on ras. Nature. 1993, 363: 88-92. 10.1038/363088a0.CrossRefPubMed

21.

Skolnik EY, Batzer A, Li N, et al: The function of GRB2 in linking the insulin receptor to ras signaling pathways. Science. 1993, 260: 1953-1955.CrossRefPubMed

22.

Cheng A, Saxton T, Sakai R, et al: Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell. 1998, 95: 793-803. This paper demonstrates that Grb2 gene dosage is rate limiting for mammary gland transformation in response to expression of the PyV MT oncogene.CrossRefPubMed

23.

Daly R: The Grb7 family of signalling proteins. Cell Signal. 1998, 10: 613-618. 10.1016/S0898-6568(98)00022-9.CrossRefPubMed

24.

He W, Rose D, Olefsky J, Gustafson T: Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J Biol Chem. 1998, 273: 6860-6867. 10.1074/jbc.273.12.6860. See [25•].CrossRefPubMed

25.

Kasus-Jacobi A, Perdereau D, Auzan C, et al: Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J Biol Chem. 1998, 273: 26026-26035. 10.1074/jbc.273.40.26026. These two papers demonstrate the presence of a novel protein–protein interaction region (the BPS domain) in Grb10 and Grb14, which targets the activated kinase domain of the insulin receptor and IGF-I receptor. This may contribute to modulation of insulin receptor/IGF-I receptor signalling by these adaptors.CrossRefPubMed

26.

Stein D, Wu J, Fuqua SAW, et al: The SH2 domain protein Grb-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13: 1331-1340.PubMedPubMedCentral

27.

Fiddes RJ, Campbell DH, Janes PW, et al: Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem. 1998, 273: 7717-7724. 10.1074/jbc.273.13.7717.CrossRefPubMed

28.

Dong L, Du H, Porter S, et al: Cloning, chromosome localization, expression and characterization of a Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10γ. J Biol Chem. 1997, 272: 29104-29112. 10.1074/jbc.272.46.29104.CrossRefPubMed

29.

Daly RJ, Sanderson GM, Janes PJ, Sutherland RL: Cloning and characterization of Grb14, a novel member of the Grb7 gene family. J Biol Chem. 1996, 271: 12502-12510. 10.1074/jbc.271.21.12502.CrossRefPubMed

30.

Tanaka S, Mori M, Akiyoshi T, et al: A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest. 1998, 102: 821-827. This paper describes an association between the expression of a novel Grb7 variant and the invasive and metastatic potential of oesophageal cancers, and also demonstrates that downregulation of Grb7 expression by an antisense strategy inhibits invasion of oesophageal cancer cells in vitro.CrossRefPubMedPubMedCentral

31.

Miyoshi N, Kuroiwa Y, Kohda T, et al: Identification of the Meg1/Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene. Proc Natl Acad Sci USA. 1998, 95: 1102-1107. 10.1073/pnas.95.3.1102.CrossRefPubMedPubMedCentral

32.

Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000,

33.

Schuuring E, Vernoeven E, Litvinov S, Michalides RJAM: The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell substratum contact sites. Mol Cell Biol. 1993, 13: 2891-2898.CrossRefPubMedPubMedCentral

34.

Huang C, Ni Y, Wang T, et al: Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J Biol Chem. 1997, 272: 13911-13915. 10.1074/jbc.272.21.13911.CrossRefPubMed

35.

Huang C, Liu J, Haudenschild C, Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 1998, 273: 25770-25776. 10.1074/jbc.273.40.25770. This is the first demonstration that tyrosine phosphorylation of EMS1/cortactin on sites phosphorylated by c-Src in vitro and in vivo is required for the increase in cell motility induced by EMS1/cortactin overexpression.CrossRefPubMed

36.

Patel A, Schechter G, Wasilenko W, Somers K: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene. 1998, 16: 3227-3232. 10.1038/sj/onc/1201850.CrossRefPubMed

37.

Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv. 1993, 18: 77-94.PubMed

38.

Hui R, Campbell D, Lee C, et al: EMS1 amplification can occur independently of CCND1 or INT2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 1997, 15: 1617-1623. 10.1038/sj/onc/1201311. The finding that EMS1 amplification, unlike that of CCND1, is associated with poor prognosis in ER-negative patients suggests that EMS1 function is regulated differently in this patient subset, possibly due to overexpression of the EGF receptor and erbB2.CrossRefPubMed

39.

Hui R, Ball J, Macmillan R, et al: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene. 1998, 17: 1053-1059. 10.1038/sj/onc/1202023.CrossRefPubMed

40.

van Damme H, Brok H, Schuuring-Scholtes E, Schuuring E: The redistribution of cortactin into cell-matrix contact sites in human carcinoma cells with 11q13 amplification is associated with both overexpression and post-translational modification. J Biol Chem. 1997, 272: 7374-7380. 10.1074/jbc.272.11.7374.CrossRefPubMed

41.

Campbell D, Sutherland R, Daly R: Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res. 1999, 59: 5376-5385. This study identified phosphorylation by the MAPKs as a mechanism for regulation of EMS1 function by the EGF receptor.PubMed

Title: Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates
Authors: Rania Kairouz
Roger J Daly
Publication date: 01-06-2000
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 3/2000
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr54

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2000

Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors

Linear and cooperative signaling: roles for Stat proteins in the regulation of cell survival and apoptosis in the mammary epithelium

Type V collagen induces apoptosis of 8701-BC breast cancer cells and enhances m-calpain expression

Homeobox genes in mammary gland development and neoplasia

Tyrosine kinase signalling in breast cancer

Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor - convergence point for signal integration and diversification

Keynote webinar | Spotlight on antibody–drug conjugates in cancer